Lakefront Biotherapeutics (LKFT) Current Leases (2015 - 2026)

Lakefront Biotherapeutics (LKFT) has 11 years of Current Leases data on file, last reported at $1.9 million in Q1 2026.

• Current Leases for Q1 2026 came in at $1.9 million, down 42.59% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.9 million (down 42.59% YoY), and the FY2025 annual result was $2.0 million, down 45.86% from the prior year.
• Current Leases retreated to $1.9 million in Q1 2026 per LKFT's latest filing, from $2.0 million in the prior quarter.
• Over five years, Current Leases peaked at $7.9 million in Q1 2022 and troughed at $1.9 million in Q1 2026.
• A 5-year average of $4.4 million and a median of $4.5 million in 2024 frame the typical range for Current Leases.
• The sharpest annual moves came in 2022 and 2025: Current Leases fell 10.75% in 2022, then tumbled 56.21% in 2025.
• A 5-year view of Current Leases shows it stood at $7.4 million in 2022, then tumbled by 31.95% to $5.0 million in 2023, then slipped by 25.73% to $3.7 million in 2024, then slumped by 45.86% to $2.0 million in 2025, then retreated by 7.86% to $1.9 million in 2026.
• Business Quant data shows LKFT's Current Leases at $1.9 million in Q1 2026, $2.0 million in Q4 2025, and $2.0 million in Q3 2025.